Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Oncogenic EGFR mutations are common in lung adenocarcinoma and often coexist with tumor suppressor gene alterations.
• The specific roles of these co-occurring genetic alterations in tumor progression and therapeutic response in vivo are not well understood.

Purpose of the Study:

• To investigate the in vivo effects of inactivating specific tumor suppressor genes on EGFR-driven lung adenocarcinoma growth.
• To determine how these genetic alterations influence response to EGFR-targeted therapy.

Main Methods:

• Utilized a mouse model of EGFR-driven, Trp53-deficient lung adenocarcinoma.
• Quantified the impact of inactivating 10 putative tumor suppressor genes on tumor growth.
• Assessed the effect of KEAP1 inactivation on tumor sensitivity to osimertinib.

Main Results:

• Inactivation of Apc, Rb1, or Rbm10 significantly promoted tumor growth in the EGFR-driven model.
• Unexpectedly, Lkb1 or Setd2 inactivation reduced EGFR-driven tumor growth, contrasting their effects in KRAS-driven models.
• KEAP1 inactivation diminished sensitivity to osimertinib, and KEAP1 pathway mutations correlated with shorter tyrosine kinase inhibitor treatment duration in patients.

Conclusions:

• The impact of genetic alterations on tumor growth and therapy response is context-dependent, varying between oncogenic drivers (EGFR vs. KRAS).
• Specific tumor suppressor genes, such as Apc, Rb1, and Rbm10, act as critical constraints on EGFR-mutant lung adenocarcinoma growth.
• KEAP1 inactivation represents a mechanism of resistance to EGFR inhibitors like osimertinib, highlighting its therapeutic relevance.